STK11 and metabolic dysfunction-associated steatotic liver disease: Additionally, a previous study from Zhao ZH’s study suggested that NaB acts as a suppressor of hepatic lipogenesis in NAFLD, attenuating hepatic steatosis, and improving lipid profiles and liver function predominantly via the liver kinase B1-AMP-activated protein kinase (AMPK)-insulin-induced gene signaling pathway in NAFLD mice models [18].